Trenton, October 11, 2024 ― The HealthCare Institute of New Jersey released the following statement concerning the Federal Trade Commission’s (FTC) final Hart-Scott-Rodino (HSR) premerger notification rules issued yesterday:
“The final HSR rules as issued by the Federal Trade Commission will impose a significant burden on the future of New Jersey’s life sciences community and our ability to do what we do best – saving lives around the world by finding new treatments and cures in New Jersey. Mergers and acquisitions have, for decades, played a vital role in facilitating a dynamic process in New Jersey that brings discoveries from the lab to patients. These rules could lead to additional costs far exceeding what many early-stage biopharmaceutical or medical technology companies are able to shoulder. We implore federal policymakers to recognize the potential damage these policies could inflict on New Jersey’s life sciences ecosystem and our state’s workforce and economy, and to restore bipartisan balance to merger and acquisition enforcement in the life sciences.”